Trial Profile
Dose Escalation and Phase II Study of Bortezomib (IND 58443, NSC 681239) Added to Standard Daunorubicin and Cytarabine Therapy for Patients With Previously Untreated Acute Myeloid Leukemia Age 60-75 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2013
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 1 Jul 2013 to 1 Mar 2020 as reported by ClinicalTrials.gov.